法巴银行：强生新药加入银屑病市场艾伯维(ABBV.US)王牌药物Skyrizi面临挑战_老虎社区_美港股上老虎

法巴银行：强生新药加入银屑病市场艾伯维(ABBV.US)王牌药物Skyrizi面临挑战

智通财经03-19

智通财经APP注意到，周三，艾伯维(ABBV.US)股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司(JNJ.US)与 Protagonist Therapeutics(PRGX.US)新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局(FDA)已批准 Icotyde 上市。这是一种每日一次的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2620143022?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-19 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620143022","market":"hk","top_or_hot":-1,"title":"法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战","media":"智通财经","content":"<div>\n<p>智通财经APP注意到，周三，艾伯维(ABBV.US)股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司(JNJ.US)与 Protagonist Therapeutics(PRGX.US)新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局(FDA)已批准 Icotyde 上市。这是一种每日一次的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415854.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n法巴银行：强生新药加入银屑病市场 艾伯维(ABBV.US)王牌药物Skyrizi面临挑战\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 14:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1415854.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP注意到，周三，艾伯维(ABBV.US)股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司(JNJ.US)与 Protagonist Therapeutics(PRGX.US)新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局(FDA)已批准 Icotyde 上市。这是一种每日一次的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415854.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066051811.HKD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1415854.html","article_id":"2620143022","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620143022","pubTimestamp":1773903308,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP注意到，周三，艾伯维股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司与 Protagonist Therapeutics新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局已批准 Icotyde 上市。不过，泰指出，鉴于 Skyrizi 强大的疗效及其每季度一次的注射频率，艾伯维在斑块状银屑病领域仍处于有利地位。泰还提到，针对 Icotyde 在银屑病关节炎等其他炎症性疾病中的持续研究，她认为这“可能代表着对 Skyrizi 的额外竞争”。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161121":"银行","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","ABBV":"艾伯维公司","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","BK4566":"资本集团","JNJ":"强生","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK4559":"巴菲特持仓"},"translate_title":"BNP Paribas: Johnson & Johnson's new drug joins psoriasis market AbbVie's (ABBV.US) ace drug Skyrizi faces challenges","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161121":1.5,"JNJ":1.5,"ABBV":1.5},"content_text":"智通财经APP注意到，周三，艾伯维(ABBV.US)股价下跌超5%，此前法国巴黎银行指出，其免疫学明星药物Skyrizi可能面临来自强生公司(JNJ.US)与 Protagonist Therapeutics(PRGX.US)新近获批的斑块状银屑病口服药物Icotyde的竞争。强生与 Protagonist于周三宣布，美国食品药品监督管理局(FDA)已批准 Icotyde 上市。这是一种每日一次的口服疗法，为中重度斑块状银屑病(一种皮肤相关的炎症性疾病)患者提供了一种全新的治疗选择。分析师纳万·泰在研究报告中写道，“Icotyde 的获批可能代表着艾伯维 Skyrizi 的竞争对手出现了，”她补充称，强生计划将该药物定位为一线疗法，与其注射剂药物 Tremfya 并行。不过，泰指出，鉴于 Skyrizi 强大的疗效及其每季度一次的注射频率(在初始剂量之后)，艾伯维在斑块状银屑病领域仍处于有利地位。与每日一次的口服给药相比，这种频率在用药依从性上具有优势。该分析师写道：“两家公司都表示，口服药物的进入可能有助于扩大市场，提供更多准入机会，并将目前的渗透率从 30-40% 进一步提升。我们认为，这意味着 Skyrizi 仍有增长空间。”泰还提到，针对 Icotyde 在银屑病关节炎等其他炎症性疾病中的持续研究，她认为这“可能代表着对 Skyrizi 的额外竞争”。尽管如此，她预测 Skyrizi 在 2026 财年的销售额将同比增长 23%，这意味着 2025-2028 财年的复合年增长率(CAGR)将达到 14%，从而为艾伯维提供重要的增长动力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}